Augnition Labs Announces FDA Classification for Flagship Product, AugMem(TM)
NEW YORK CITY, NEW YORK / ACCESS Newswire / June 12, 2025 / Augnition Labs, a neurotechnology company developing science-driven tools to advance cognitive health, today announced that its flagship product, AugMem™, has been classified by the FDA as a Prescription Use Cognitive Assessment Aid (PTY). This significant milestone paves the way for clinical deployment to support evaluation of cognitive function and help identify changes that may indicate early cognitive decline.
Grounded in more than two decades of neuroscientific research by Co-Founder and Chief Scientific Advisor, Dr. Michael Yassa, AugMem™ evaluates pattern separation - a core brain process that enables us to form distinct memories. Subtle impairments in this mechanism often precede clinical symptoms of cognitive decline by 10-15 years.
"Early detection is critical. If we wait until memory loss is obvious, decline can be irreversible," said Yassa. "This FDA classification is a major step forward. It opens the door for us to deploy it in healthcare settings. Our goal is to make ultrasensitive cognitive assessment available where it's needed most-at the frontlines of care, before symptoms become disabling."
In addition to this regulatory milestone, Augnition Labs also announced key leadership appointments to strengthen its path to growth and impact. Ernst Wodrada, a seasoned executive in the medical technology industry, has joined Augnition as President. Ernst brings leadership experience from global healthcare organizations, including Philips, where he led efforts in imaging, image-guided therapy, and healthcare innovation.
"I am honored and excited to join Augnition Labs, working alongside this fantastic team to forge meaningful partnerships with clinical experts and investors," Wodrada said. "Cognitive decline presents profound challenges, and together, we are committed to pioneering solutions that empower individuals and caregivers."
Ali Kennedy Scott, a member of Augnition's founding team, will step into the role of Managing Director. A former Bain & Company consultant, Kennedy Scott brings expertise in growth strategy, organizational effectiveness, and customer insight, with experience spanning healthcare, consumer products, and private equity-backed ventures.
The company also welcomes Dr. Chris Bun as Head of Technology. With a background in AI, machine learning, and healthcare technology, Dr. Bun will lead development of Augnition's core platform, applying advanced AI and user-centered design to cognitive assessment tools.
"We are deeply proud of the momentum behind AugMem™ and of this team that's come together to shape the future of cognitive assessments," said Kennedy Scott. "This FDA classification is a foundational step in our mission to equip patients, caregivers, and healthcare providers with tools that enhance clarity, agency, and hope."
Augnition collaborates with leading academic institutions, industry researchers, clinicians, and healthcare systems to create accessible, evidence-based tools for cognitive health.
About Augnition LabsAugnition Labs develops science-driven tools to advance cognitive health. The company was founded on the scientific work of Dr. Michael Yassa, a globally recognized expert in the neurobiology of memory and Alzheimer's Disease. With a focus on clinical utility, human-centered design, and early intervention, Augnition empowers patients, researchers, and clinicians to better understand the brain and respond to change.
www.augnitionlabs.com
SOURCE: Augnition Labs
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Urgent dried fruit recall in 19 states over serious health risk
Dried fruit sold in multiple states has been recalled due to a serious health risk. Turkana Food Inc issued a recall on 352 cases of its Floria Dried Apricots, according to a press release shared by the U.S. Food and Drug Administration on Thursday. The product was recalled because it contains an undeclared allergen, sulfites, or 'chemicals used as preservatives' added to foods, beverages, and medications to prevent them from spoiling, according to the Cleveland Clinic. According to the FDA, the recall came after routine sampling, performed by the New York State Department of Agriculture, revealed that the product contained sulfites, which 'were not listed on the product labeling.' As Turkana Food Inc continues an 'investigation to correct the issue with the manufacturer,' production and distribution of the product by the FDA has been ceased. The recalled Floria Dried Apricots were sold at stores in 19 states: Alabama, California, Florida, Illinois, Indiana, Kentucky, Massachusetts, Maryland, Michigan, Missouri, New Jersey, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, Tennessee, Texas, and Virginia. The product has the LOT number 440090478-15-333 on the bottom portion of the packaging. The UPC Label 2539560010 is marked by a sticker on the side of the packaging. The expiration date of November 2026 is also on the bottom of the packaging. Consumers who have the recalled product should not consume it. The FDA is also urging consumer to return the dried apricots to the place of purchase for a full refund. There have been no reported illnesses so far. Most often, people with asthma have allergies and sensitivities to sulfites. Earlier this week, P. East Trading Corp. also urgently recalled its Salted Smoked Split Herring because it may have been contaminated with Clostridium botulinum, a bacterium that can cause illness or death. Botulism is a rare but serious condition caused by a toxin that attacks the body's nerves. Symptoms include general weakness, dizziness, double-vision, trouble with speaking or swallowing, difficulty in breathing, abdominal distension, and constipation. Then, on Tuesday, 6,668 cases of Breyers Chocolate Truffle Ice Cream was also recalled following customer concerns that there was a mislabeling error. The recall came after it was found that the tubs actually contained Rocky Road ice cream. The Chocolate Truffle flavor has an allergen label that reads, 'may contain tree nuts,' while the Rocky Road flavor declares almonds as one of the ingredients. The last two years have also seen an alarming and unexplained rise in recalls. In 2024, approximately 300 food recalls were issued, with those recalls being linked to nearly 1,400 illnesses, a Public Interest Research Group report revealed. Out of the 1,400 illnesses, 487 people became sick enough to require hospitalization, and 19 people died. While those numbers are still low when weighed against the entire U.S. population, they are also double the number of hospitalizations and deaths from food-borne illnesses in 2023.
Yahoo
31 minutes ago
- Yahoo
Insmed Incorporated (INSM) Soars on Positive PAH Therapy Trial Results
Insmed Incorporated (NASDAQ:INSM) is among the 10 Best Growth Stocks Under $100 to Buy Now. The shares of Insmed Incorporated (NASDAQ:INSM) have witnessed a surge of about 32% in the course of five days following the success of Phase 2b of its once-daily pulmonary arterial hypertension (PAH) therapy, treprostinil palmitil inhalation powder (TPIP). The results were evaluated about 24 hours after the administration of the drug, showcasing a consistent benefit throughout the 24-hour dosing period. Additionally, the company has revealed plans to initiate discussions with the U.S. Food and Drug Administration (FDA) to shape its Phase 3 trials roadmap. While this first Phase 3 trial will focus on pulmonary hypertension tied to interstitial lung disease by the year's end, the second trial is designed for PAH patients in the coming year. By 2032, the global market for pulmonary arterial hypertension is set to climb to $12.2 billion. A biopharmaceutical research team taking notes in front of a laboratory's microscope. The two anticipated phase 3 studies are enough to be excited about the company, yet there exists another breakthrough. Insmed Incorporated (NASDAQ:INSM) has finalized and submitted its New Drug Application (NDA) of brensocatib for treating patients with Non-cystic fibrosis bronchiectasis (NCFBE), with the date for review set for August 12, 2025. The company is indeed among the companies with high growth potential. Insmed Incorporated (NASDAQ:INSM) is a New Jersey-based biopharmaceutical company that develops and markets therapies to treat patients with serious and rare diseases. With a global presence, the company is committed to transforming the lives of many. While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
44 minutes ago
- Yahoo
Check Your Freezer—Popular Ice Cream Recalled Due To Potentially Life-Threatening Allergen
Summer is just around the corner and ice cream is the quintessential warm weather treat. But if you have a carton or two chilling in your freezer, you might want to check the label. Breyers recently issued a recall on 6,668 cases of ice cream due to "undeclared allergens and mislabeled product." According to the FDA, the voluntary recall was initiated on June 2 because Breyers Rocky Road, which contains the almonds, was packaged incorrectly. The ice cream was packaged in Breyers Chocolate Truffle tubs with Rocky Road lids, which may be a concern for anyone who purchased the product and has a nut allergy. While almonds are a tree nut, the Chocolate Truffle tubs offer misleading ingredient information. The tubs say "may contain tree nuts" while the lids say "contain almonds." The FDA classified the recall as a Class II, which is defined as "a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." So how do you know if your ice cream is affected? Take a peek at the packaging of your Breyers ice cream tub. Affected products have the lot number: JUL1026GB3 and UPC code: 077567457288. In a statement to PEOPLE, Breyers says: "People with an almond allergy should not consume the product due to risk of serious or life-threatening allergic reaction. The safety and quality of our products is our top priority. For more information, consumers can visit or call 1-800-931-2826." You Might Also Like Insanely Easy Weeknight Dinners To Try This Week 29 Insanely Delicious Vodka Cocktails
